$0.828700
0.044.41%
Pre-Market: 6:15 AM EDT
Comments
Loading...
Adaptimmune Therapeutics (ADAP) Forecast
NewsEarningsAdaptimmune Therapeutics (ADAP) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Quotes, Forecast and News Summary
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Adaptimmune Therapeutics (ADAP) stock?
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Who are Adaptimmune Therapeutics (ADAP) competitors?
Other companies in Adaptimmune Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Cabaletta Bio (NASDAQ:CABA), Galectin Therapeutics (NASDAQ:GALT), Atossa Therapeutics (NASDAQ:ATOS) and Eledon Pharma (NASDAQ:ELDN).
What is the forecast, or price target, for Adaptimmune Therapeutics (ADAP) stock?
Adaptimmune Therapeutics has a consensus price target of $4.26.
What is the current price for Adaptimmune Therapeutics (ADAP)?
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $0.8287 last updated November 13, 2024 at 6:15 AM EST.
Does Adaptimmune Therapeutics (ADAP) pay a dividend?
There are no upcoming dividends for Adaptimmune Therapeutics.
When is Adaptimmune Therapeutics (NASDAQ:ADAP) reporting earnings?
Adaptimmune Therapeutics’s Q3 earnings are confirmed for Wednesday, November 13, 2024.
Is Adaptimmune Therapeutics (ADAP) going to split?
There is no upcoming split for Adaptimmune Therapeutics.
What sector and industry does Adaptimmune Therapeutics (ADAP) operate in?
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.